MedTech and Biotech Earnings: Profound Medical and Atea Signal 2026 Pivot

The conclusion of the 2025 fiscal year has provided a definitive look at the diverging paths of commercial-stage medical technology and clinical-stage biotechnology. The fourth-quarter earnings reports from Profound Medical (PROF) and Atea Pharmaceuticals (AVIR) highlight a broader industry trend: the prioritization of high-margin recurring revenue in med-tech and the strategic management of cash runways in the biotech sector. As the healthcare market moves further away from the pandemic-era investment frenzy, these results underscore a return to fundamental performance metrics, specifically reimbursement success and late-stage clinical data readouts.

Profound Medical’s fourth-quarter results reflect a pivotal year for the TULSA-PRO system, a transurethral ultrasound ablation technology for prostate cancer. Throughout 2025, Profound’s primary challenge was not just the placement of new capital equipment, but the conversion of those placements into consistent, high-volume procedure revenue. The company’s focus on the U.S. market has been bolstered by favorable shifts in the reimbursement landscape, particularly as private insurers begin to align with Medicare’s coverage of non-invasive prostate therapies. For investors, the key metric in Profound’s Q4 report is the growth in recurring revenue from disposables and service contracts, which now represents a larger share of total revenue than one-time system sales. This shift toward a "razor-and-blade" model is critical for the long-term sustainability of medical device firms in a high-interest-rate environment where hospital capital budgets remain under pressure.

“

Profound Medical’s fourth-quarter results reflect a pivotal year for the TULSA-PRO system, a transurethral ultrasound ablation technology for prostate cancer.

In contrast, Atea Pharmaceuticals’ 2025 performance is defined by its clinical pipeline and capital preservation. Atea has spent the last year pivoting its antiviral platform, centered on bemnifosbuvir, from a singular focus on COVID-19 to a broader application in Hepatitis C (HCV) and other respiratory viruses. The fourth-quarter update emphasizes the progress of the SUNSET Phase 3 trial for COVID-19 and the Phase 2 trial for HCV. For clinical-stage biotechs like Atea, the earnings report is less about revenue and more about the "burn rate" and the remaining cash runway. Atea entered 2026 with a significant cash position, which provides a buffer against the volatility of the biotech capital markets. This financial stability is a competitive advantage, allowing the company to fund its late-stage trials through to critical data readouts without the immediate need for dilutive financing.